Finding the right immune cell candidates is one of the greatest challenges in cellular immunotherapy. We do not just help you find immune cells, we help you find the right ones. Our pioneering microfluidic platform revolutionises the discovery process by rapidly screening, characterising, sorting, and isolating live, tumour-reactive immune cells — all in a single streamlined process.
Unlike conventional methods that focus only on single receptor binding (affinity), our platform measures cellular avidity — the total binding strength between living immune and cancer cells — giving you a far deeper, physiologically relevant insight into therapeutic potential. And because we preserve cell viability and function, you can immediately move forward with further development, without starting from scratch.
- Unmatched Throughput: We screen thousands of immune cells simultaneously.
- Superior Candidate Selection: We identify, sort, and recover high-avidity immune cells that are most likely to succeed in vivo from samples of unknown immune cells
- Physiologically Relevant Data: We enable you to make better decisions with holistic insights into immune-cancer cell interactions, far beyond what affinity alone can reveal.
- Broad Compatibility: We can extract high-avidity immune cells across a wide range of cell types, disease models, and therapeutic modalities — from TCR-T to NK cells.
We are here to help you take your immunotherapy to the next level. Get in touch with us, and together we will explore custom solutions tailored to your unique needs. Our team is dedicated to providing the insights that will ensure your therapy’s success. Let us work together to bring your innovative treatment to patients.
